All In Biotech

Drug Trial Radar · NCT05400369

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Aug 10, 2022

Primary completion

Sep 25, 2024

Study completion Sep 25, 2024

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation. Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections. This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.

Conditions

  • COPD Exacerbation Acute

Interventions

  • SitafloxacinDrug

    Oral administration, 50 mg tablets

  • Moxifloxacin HydrochlorideDrug

    Oral administration, 400 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving Clinical Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseTime frame: End of treatment (approximately Day 10 post-dose)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Shougang Hospital

    Beijing, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • The Sixth People's Hospital of Chengdu

    Chengdu, China

  • West China Hospital Sichuan University

    Chengdu, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, China

  • Fuyang People's Hospital

    Fuyang, China

  • Nanfang Hospital Southern Medical University

    Guangzhou, China

  • Qilu Hospital of Shandong University

    Jinan, China

  • Gaozhou People's Hospital

    Maoming, China

  • Huadong Hospital Affiliated To Fudan University

    Shanghai, China

  • Shenzhen People's Hospital

    Shenzhen, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • The Sixth Hospital of Wuhan

    Wuhan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, China

  • Henan Provincial People's Hospital

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.